| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
AD-Detect™ p-tau217/Beta-Amyloid 1-42 Ratio, Plasma (FDA Cleared)
Test Code17970
CPT Codes
84393, 82234
Includes
ptau217
ABeta 42
ptau217/ABeta 42 Ratio
ABeta 42
ptau217/ABeta 42 Ratio
Preferred Specimen
1 mL plasma collected in a K2 EDTA (lavender-top) tube
Minimum Volume
0.75 mL
Instructions
Centrifuge sample within 2 hours of collection and transfer to a polypropylene tube for transport.
Freeze within 24 hours. Transport frozen.
Freeze within 24 hours. Transport frozen.
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: 24 hours
Frozen: 30 days
Refrigerated: 24 hours
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Moderate or gross hemolysis
Methodology
Fujirebio Lumipulse Chemiluminescent Enzyme Immunoassay
Setup Schedule
Set up: Mon-Sat; Report available: 3-5 days
Clinical Significance
AD-Detect™ p-tau217/Beta-Amyloid 1-42 Ratio, Plasma (FDA Cleared) is cleared by the FDA for assessment of patients aged >=50 years with signs or symptoms of cognitive decline. The levels of two proteins, p-tau217 and Beta-amyloid 1-42, are evaluated within the plasma and calculated into an analytical ratio. This ratio is correlated to the presence or absence of amyloid plaques in the patient s brain, which may reduce the need for an amyloid-PET scan.
